Employees: 597
Size Sanofi Consumer Healthcare India (SANOFICONR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $869M, the 644th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,532 on 18 Nov 2026.
Performance Over six months the shares fell 26.2%, against -22.8% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 19 in its peer set.
Growth Revenue grew 22.7% over the last twelve months (peer median +1.4%); the operating margin is 36.4% (peer median -0.8%).
Valuation It trades at 28.1× forward earnings against a peer median of 25.2× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 57.0 points above its cost of capital (12.5% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | ₹9.79B | ₹8.78B | ₹7.24B | ₹5.55B |
| Revenue growth | — | +21% | +30% | — |
| Gross profit | ₹5.90B | ₹4.55B | ₹3.80B | ₹3.04B |
| EBITDA | ₹3.70B | ₹3.13B | ₹2.75B | ₹2.19B |
| Net income | ₹2.80B | ₹2.40B | ₹1.81B | ₹1.65B |
| Free cash flow | n/a | ₹1.83B | ₹4.41B | -₹4.00M |
| Capital expenditure | n/a | ₹76.0M | ₹99.0M | ₹40.0M |
| Total debt | n/a | ₹248M | ₹203M | ₹0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SANOFICONR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | -11.6% | 2nd highest of 21 |
| 6-month return | -26.2% | -22.8% | 9th lowest of 19 |
| Distance from 52-week high | -32.8% | -43.7% | 6th highest of 21 |
| Revenue growth (TTM) | +22.7% | +1.4% | 4th highest of 19 |
| Operating margin | 36.4% | -0.8% | highest of 19 |
| Forward P/E | 28.1× | 25.2× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 17.7% | 10.9% | 4th least demanding of 7 |
| Growth delivered (Del g) | +22.7% | +1.7% | highest of 7 |
| Hurdle (Req g minus delivered) | -4.9 pp | +9.3 pp | 4th least demanding of 7 |
| ROIC minus cost of capital | +57.0 pp | -2.9 pp | highest of 15 |
| EV / EBITDA | 22.0× | 8.8× | most expensive of 6 |
| Net debt / EBITDA | -0.9× | -0.3× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |